TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...

Vinay Prasad, a top FDA official, blamed COVID shots for playing a role in the deaths of 10 children in a memo he sent to ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become ...

Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...

Moderna MRNA-6.55%decrease; red down pointing triangle swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating ...

Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 – $5.4 billion Increases 2025 expected year-end cash balance by $0.5 billion – $1 billion to a range of $6.5 – $7.0 ...